Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Wall Street witnessed a historic day with the S&P 500 and Dow Jones Industrial Average reaching record highs. The Russell ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。